Tesamorelin vs MK-677

Tesamorelin wins for:

• Dramatic, MRI-proven reduction of visceral adipose tissue (VAT) and liver fat (NAFLD). No other compound can touch its visceral selectivity at clinically-validated doses (1–2 mg SC daily).
• Predictable, pulse-like induction of endogenous GH/IGF-1 without the extended elevated cortisol or hunger spikes seen with ghrelin agonists. Lower water retention and bloat relative to MK-677.
• Cleanest choice for midsection recomposition, especially for AAS/TRT/insulin users battling 'GH gut' or stubborn metabolic syndrome markers.

MK-677 wins for:

• Simplicity and convenience — oral, long half-life (24h+), zero injection protocols, ultra-accessible even for peptide-adverse users.
• Broad-spectrum GH/IGF-1 elevation: not as fat-specific as tesamorelin, but reliably drives lean mass, recovery, and slow-wave sleep across age groups.
• Stackability and approachability for year-round use: 2-year safety data, no tachyphylaxis, friendly with SARMs/TRT, and ideal for bridging or connective-tissue repair.

Both have glucose management considerations, but tesamorelin's VAT reduction can actually improve metabolic markers, while MK-677 can worsen insulin sensitivity if pushed too hard or run year-round.

Pick Tesamorelin if:

• You want maximal, MRI-proven reduction in visceral fat or fatty liver (NAFLD), especially post-blast or after extended GH/insulin cycles.
• You're targeting 'GH gut' and abdominal distension with minimal impact on subcutaneous fat or lean mass.
• Metabolic health, triglycerides, or ALT/AST markers are a real concern and you want a tool for aggressive VAT/liver fat recomposition.
• You're peptide-experienced and fine with daily 1–2 mg subcutaneous injections.
• You want a lower appetite increase and the least possible water retention or subq bloat.

Pick MK-677 if:

• You want the simplest, most sustainable GH/IGF-1 elevation — oral dosing, no injection skills, and all-rounder benefits (sleep, skin, joint recovery, muscle retention).
• You're running a lean bulk or SARM/trt stack and want to leverage higher IGF-1 for bodycomp, sleep, or recovery, but subq peptides are a no-go.
• Injury rehab, tissue recovery, or general anabolic 'bridge' support is the main play, not targeted visceral fat loss.
• You can manage increased appetite, transient water retention, or mild increases in fasting glucose.
• You want a year-round tool with long safety data and no axis suppression or PCT issues.